Mathematical models have suggested that SARS-CoV-2-induced ACE2 downregulation perturbs RAS homeostasis, and interventions targeting RAS components predicted an improvement of the clinical outcome of COVID-19 for some drugs and a worsening for others [20]. The gene discussed is ACE2; the disease is COVID-19.